secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-05-13T20:33:41+00:00
Accession:  0001104659-26-060299
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan
--------------------------------------------------------------------------------

- Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.
- Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.
- Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.
- AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.
- Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-060299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer